512 related articles for article (PubMed ID: 22036021)
1. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
J Am Acad Dermatol; 2008 Jan; 58(1):125-35. PubMed ID: 17996329
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
5. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
6. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
Ferrándiz C; García A; Blasco AJ; Lázaro P
J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
[TBL] [Abstract][Full Text] [Related]
7. Experience with the systemic treatment of severe forms of psoriasis.
Tichý M; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Mar; 156(1):29-40. PubMed ID: 22580858
[TBL] [Abstract][Full Text] [Related]
8. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
[TBL] [Abstract][Full Text] [Related]
9. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
Bagel J
J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
[TBL] [Abstract][Full Text] [Related]
11. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
12. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
13. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B
Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis.
De Simone C; D'Agostino M; Capizzi R; Capponi A; Venier A; Caldarola G
Eur J Dermatol; 2011; 21(4):568-72. PubMed ID: 21697032
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
[TBL] [Abstract][Full Text] [Related]
16. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
D'Souza LS; Payette MJ
J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser.
Park KK; Swan J; Koo J
Dermatol Online J; 2012 Mar; 18(3):2. PubMed ID: 22483513
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
19. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.
Park KK; Wu JJ; Koo J
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):899-906. PubMed ID: 22702846
[TBL] [Abstract][Full Text] [Related]
20. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
